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Abstract
After reaching a nadir at the turn of the century, syphilis rates in the United States have increased 
since 2000. T. pallidum may disseminate to the central nervous system within hours to days after 
inoculation. In this review, we focus on knowledge gaps and areas of controversy in neurosyphilis 
epidemiology, diagnosis, and management. Modern estimates of the prevalence of neurosyphilis 
are hindered by the lack of consistent reporting data and are based on relatively small retrospective 
cohort studies. The various diagnostic modalities for neurosyphilis have significant limitations. 
While several novel biomarkers for neurosyphilis have been evaluated, none to date have found a 
place in clinical practice. The role of a cerebrospinal fluid examination in patients without 
neurological symptoms continues to be an area of controversy, while the data for the use of 
antibiotic regimens other than intravenous aqueous or intramuscular procaine penicillin for the 
treatment of neurosyphilis are limited. As syphilis incidence continues to increase unabated in 
many countries around the world, it is critical to address these gaps of knowledge.
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After reaching a nadir at the turn of the century, syphilis rates in the United States have 
increased steadily since then.1 Neurologic manifestations of syphilis may occur during any 
stage of the infection. Animal models demonstrate that T. pallidum disseminates to the 
central nervous system within hours to days after inoculation.2 While there have been 
several recent reviews on neurosyphilis,3,4 our goal here is to focus on knowledge gaps and 
areas of controversy in the epidemiology, diagnosis, and management of neurosyphilis.
Epidemiology
Rates of neurosyphilis in the United States are not known. Syphilis is a reportable condition 
but reporting of neurosyphilis cases is inconsistent mainly because the surveillance 
definitions (see below) require data that are not often available. Much of what we know 
about the epidemiology of neurosyphilis predates the penicillin era. Early neurosyphilis, 
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which manifests as meningeal or meningovascular involvement of the central nervous 
system, was rare. Merritt et al. identified only 80 cases of acute syphilitic meningitis from 
three hospitals over 15 years starting in 1920, and 37 cases amongst 2263 patients seen at 
Boston City Hospital (pp.10, 28).5 What was clear, however, was that the incidence was 
strongly dependent on therapy. Early neurosyphilis was rare among persons who were not 
treated for syphilis (0.3%) but the incidence increased nearly ten-fold in those who were 
inadequately treated (2–3%) (p.358)6-suggesting that inadequate or incomplete treatment 
may alter the immune response in such a way as to increase the risk for early neurosyphilis 
(termed “neurorecurrence”). Merritt et al. reported that almost 30% of all patients with 
syphilis (including early stage syphilis) had neurosyphilis, though approximately 30% of 
these cases were classified as asymptomatic (p10)5 (of note, among early neurosyphilis 
cases, Moore reported that 77% were asymptomatic).7 Merritt et al. separately estimated that 
3% (based on data from Mattauscheck and Pilcz, as well as their own data) to 15% (based on 
data from Moore) of patients infected with syphilis developed meningovascular 
manifestations (p.89).5 Late neurosyphilis (or tertiary neurosyphilis) was more common. 
The Oslo Syphilis Study published in 1929 followed untreated patients with primary and 
secondary syphilis and reported that 9.5% developed late neurosyphilis.8 Similar numbers 
were reported by Mattauschek and Pilcz in their 1913 study of 4134 cases of syphilis 
amongst Austrian army officers.5,6,9 Merritt et al. estimated (based on data from others) that 
5% developed general paresis (p.195), and (based on their own as well as data from others), 
1.5–9% developed tabes dorsalis (p.243). 5
After the introduction of penicillin in the 1940’s, cases of neurosyphilis decreased 
dramatically. In a retrospective study of all cases of neurosyphilis diagnosed and reported to 
the Danish centralized health system between 1971 and 1979, only 55 cases of neurosyphilis 
were identified, the majority of which likely represented persons who were reinfected 
following appropriate penicillin therapy.10
The onslaught of HIV corresponded with increasing numbers of reported neurosyphilis 
cases-particularly early neurosyphilis.11–13 Whether this was the result of biological 
susceptibility as a consequence of immunosuppression or increased detection as a result of 
enhanced follow-up is not known. However, robust contemporary estimates of the 
prevalence of symptomatic neurosyphilis are lacking. Those that exist have largely been 
based on small retrospective studies of health department syphilis records, often in select 
populations. A CDC analysis of reported cases of neurosyphilis in HIV positive MSM in 4 
US cities from 2002 to 2004 estimated the prevalence of early symptomatic neurosyphilis to 
be 1.7%,12 while a review of syphilis cases diagnosed in Los Angeles amongst persons aged 
19 to 65 in 2001–2004 estimated that 1.5% had confirmed or probable neurosyphilis.14 A 
retrospective study of 238 HIV and syphilis co-infected patients from a large public hospital 
found that approximately 3% had neurosyphilis.15 In a review of 573 syphilis cases in King 
County, WA from 2012–2013, 3.5% of cases met the study criteria of confirmed 
symptomatic neurosyphilis with abnormal CSF testing or an ophthalmologic examination 
consistent with ocular syphilis. A total of 7.9% had visual or hearing symptoms, which the 
authors suggest could have represented neurosyphilis.16 Finally, a study in the Netherlands 
which examined countrywide hospital discharge diagnoses of neurosyphilis from a national 
registry as well as STI clinic syphilis diagnoses estimated that 10–13% of all cases of 
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syphilis diagnosed in that country from 1999–2010 had neurosyphilis. However this estimate 
was based on hospital discharge diagnoses rather than documented clinical examination or 
laboratory criteria.17
In summary, modern estimates of the prevalence of neurosyphilis are hindered by the lack of 
consistent reporting data and are based on relatively small retrospective cohort studies whose 
case definitions differ.
Diagnosis
Diagnostic Criteria
The diagnosis of neurosyphilis remains challenging as there are no gold standard tests. 
Consequently, the diagnosis is based on a combination of clinical and CSF findings. A 
potential source of confusion to the clinician is the dissonance between the Centers for 
Disease Control and Prevention’s (CDC) surveillance definition of neurosyphilis,18 and the 
clinical description of neurosyphilis found in the CDC STD Treatment Guidelines.19 This is 
not surprising given that the goal of the surveillance document is primarily epidemiological 
while that of the latter is patient management. As a practical example, while the surveillance 
document does not take syphilis stage into consideration when defining neurosyphilis, the 
treatment document recognizes that a subset of patients with early syphilis may have 
asymptomatic CSF changes (including a positive CSF VDRL) that may not warrant 
additional diagnostic or therapeutic interventions.19
Neuroinvasion and Symptoms
The relationship between T. pallidum neuroinvasion and markers of neurosyphilis (i.e. 
neurological symptoms, pleocytosis, reactive CSF VDRL and treponemal antibody tests, and 
elevated CSF protein) is complex. One challenge are the limitations of the tests to detect 
neuroinvasion (i.e. rabbit infectivity test and CSF PCR). A landmark study by Lukehart et. 
al. demonstrated that 12 of 40 (30%) participants with early syphilis had evidence of 
neuroinvasion compared to 0 of 17 with latent syphilis (Lukehart’s estimate of neuroinvasion 
in early syphilis is remarkably consistent with estimates from multiple investigators dating 
back to the early 1900s). While those with documented neuroinvasion appeared more likely 
to exhibit neurological symptoms (50% vs. 26%), CSF pleocytosis (64% vs.32%), elevated 
protein (50% vs. 21%), and reactive CSF VDRLs (33% vs. 14%), a significant number of 
participants with documented neuroinvasion did not exhibit these abnormalities. 
Surprisingly, neither HIV status nor reactive CSF treponemal antibodies appeared to be 
related to neuroinvasion.20 While neuroinvasion may be transient, predictors of its 
persistence and the likelihood of resulting pathological changes are not well established.
A common question arises: Can a diagnosis of neurosyphilis be made in the presence of a 
normal CSF examination? While a normal CSF examination may be present in nearly 40% 
of persons with ocular syphilis21 and over 90% of persons with otic syphilis,22 a normal 
CSF (cells, protein, and serology) excludes most cases of neurosyphilis except (perhaps) for 
a subset of persons with tabes (two of 100 patients with tabes in Merritt’s case series had a 
completely normal CSF, as well as negative blood serologies) (p.282).5 It’s worth noting that 
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Moore reported a broad array of symptoms in early syphilis ranging from mild 
(“neurosyphilis manifested by mild symptoms or slight physical signs, not of themselves 
diagnostic of central nervous system damage”) to severe with increasing symptom severity 
reflected in more pronounced CSF abnormalities (p. 345).6 This association between 
symptoms and CSF abnormalities was not observed in persons with late syphilis.
CSF VDRL
The lipoidal (or non-treponemal) test that is most commonly used to diagnose neurosyphilis 
from CSF is the VDRL. The test is thought to be highly specific in the absence of gross 
blood contamination.3,23 CDC guidelines do not recommend use of the CSF RPR because of 
its lower sensitivity.24,25 While there have been reports of false positive VDRLs in the CSF 
(e.g. with meningeal carcinomatosis, spinal cord tumor, trypanosomiasis, and cerebral 
malaria)5,23,26, these occurred in patients without serological evidence of syphilis (in whom 
sending the CSF VDRL would not generally be appropriate). In practice, a reactive CSF 
VDRL is regarded as synonymous with a diagnosis of neurosyphilis. The sensitivity of the 
CSF VDRL, however, is still debated3,27 because the lipoidal test that predated the VDRL, 
the CSF Wasserman, had a very high sensitivity for neurosyphilis: It was reactive in 86% of 
patients with early syphilitic meningitis (p.44)5 and in all patients with paretic neurosyphilis 
(p. 383)5, though 28% of patients with tabes dorsalis-particularly those with the later stages 
or “burned out” tabes-had a negative CSF Wasserman (p. 385).5 It was even suggested that 
these numbers were underestimates as most of these cases occurred prior to the recognition 
of syndromes such as extracranial carotid artery disease, cerebral arteritis, basilar artery 
insufficiency, lacunar syndromes and viral meningoencephalitis, which may have accounted 
for some of the CSF abnormalities attributed to syphilis in persons with a nonreactive CSF 
Wasserman.28,29 The current sensitivity estimate for the CSF VDRL is about 50–60%. The 
most frequently cited data for this estimate emanate from a large neurosyphilis case series 
published in 1972 by Hooshmand et al, involving 241 patients. Of the 176 patients who were 
tested, 43% had a nonreactive CSF VDRL, almost twice the number that had been 
previously reported to be nonreactive with the CSF Wasserman.3,30 Not surprisingly, the 
case selection in the Hooshmand paper has been questioned, with experts suggesting that 
some of these patients may not have had neurosyphilis.27,31s It’s worth noting that most 
papers published in the modern era have suggested a CSF VDRL sensitivity of 50–60%,
32,33s
 but similar critiques could be leveled against these estimates. At the heart of this 
controversy is the lack of an alternative gold standard to make the diagnosis of 
neurosyphilis. While some experts have suggested that a clinical diagnosis of neurosyphilis 
always requires a reactive CSF VDRL,27 it is unlikely that clinicians will withhold antibiotic 
therapy from patients with nonreactive CSF VDRLs if there is other compelling evidence for 
neurosyphilis (e.g. neurological symptoms with CSF pleocytosis and no alternate diagnosis).
CSF Treponemal Tests
The CSF treponemal antibody tests, in contrast, are felt to be relatively non-specific. Indeed, 
another critique of the Hooshmand paper was that it utilized the CSF FTA-ABS as a part of 
the criteria for the diagnosis of neurosyphilis.31s While nonspecific, the treponemal-specific 
antibodies in the CSF are thought to be highly sensitive. As per the CDC 2015 STD 
Treatment Guidelines, “Neurosyphilis is highly unlikely with a negative CSF FTA-ABS test, 
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especially among patients with nonspecific neurologic signs and symptoms.”19 What the 
guidelines suggest is that, in the absence of a test with 100% sensitivity, the negative 
predictive value depends on the pretest probability of the diagnosis. A systemic review of 
treponemal-specific CSF tests for neurosyphilis found considerable heterogeneity among 
studies with variations in reported sensitivities,34s a recent study found that the sensitivity 
for several different treponemal-specific tests ranged from 83.3% to 100%,35s and an 
additional study found similar results.33s The sensitivity of point of care CSF treponemal 
tests may be somewhat lower.36s Hence, in patients with serologic evidence of syphilis and a 
high clinical probability of neurosyphilis, a nonreactive CSF treponemal antibody test may 
not rule out neurosyphilis.34,37s These tests may be useful, however, to rule out the diagnosis 
of neurosyphilis when the pretest probability is moderate to low.
CSF Pleocytosis
In 1946, Merritt et al reported that of 80 cases of acute syphilitic meningitis, only 1 had a 
CSF analysis showing less than 10 white blood cells (WBC)/ml; 18% had a CSF with 11–50 
WBC/ml (p.42).5 In cerebral meningovascular syphilis, the cell count was less than 10 
WBC/ml in 37% of cases, and 63% had greater than or equal to 10 WBC/ml (p.127).5 In 
paretic neurosyphilis, 10% of patients had a normal cell count (p382).5 In contrast, in tabetic 
neurosyphilis, 53% had CSF WBCs ranging from 0 to 5 cells/ml (p.385).5 In a study by 
Marra et al., one of 8 patients with early syphilis diagnosed with definite neurosyphilis 
(positive CSF VDRL) had two WBC/ml in the CSF, as well as a normal protein.38s In 
Hooshmand’s study, 18.4% had <5 WBC/ml in the CSF, but this series included a large 
number of patients with tertiary neurosyphilis.30
A cutoff of >5 cells/mL in the CSF has been a standard cutoff used to define CSF 
pleocytosis. CSF pleocytosis is not specific for diagnosing neurosyphilis because multiple 
conditions, both infectious and non-infectious, can lead to elevated WBC in the CSF.39s The 
interpretation of the CSF WBC is particularly problematic in persons infected with HIV, as a 
significant number may have CSF pleocytosis independent of neurosyphilis, particularly if 
they are not on antiretroviral therapy (ART).40s Though data are limited, it has been 
suggested that a cutoff of 10 cells/mL for HIV infected patients on ART and 20 cells/mL in 
those not on ART may improve specificity for a diagnosis of neurosyphilis.41s The CSF cell 
count appears to correlate with disease activity and is typically the first parameter to improve 
following therapy (p389).5
In summary, save for a subset of patients with tabes dorsalis, it is rare to encounter patients 
with neurosyphilis who lack CSF pleocytosis. As such, pleocytosis while non-specific is a 
sensitive marker for neurosyphilis.
Elevated CSF Protein
With the exception of some trace proteins and beta globulins, CSF proteins are derived from 
serum proteins. While CSF IgG is usually derived from plasma, local synthesis within the 
CNS does occur in a variety of disorders, including neurosyphilis. Elevated CSF protein is 
caused by increased permeability of the blood-CSF barrier or increased CSF protein 
synthesis in the CNS.39s As with CSF pleocytosis, elevated protein is non-specific and may 
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be found in a variety of infectious and non-infectious conditions.39s Therefore, a diagnosis 
of neurosyphilis based only on CSF protein elevation is highly non-specific. As for its 
sensitivity, Merritt et al found that 12% of patients with acute syphilitic meningitis (p.43), 
25% of patients with general paresis (p.383), 34% of patients with cerebrovascular syphilis 
(p. 380) and 47% with tabes dorsalis had a CSF protein < 45 mg/dl (normal) (p.385).5 In 
Hooshmand’s study, 61% had a normal CSF protein, while in the study by Marra et al, 3 of 8 
patients with definite neurosyphilis had a normal CSF protein.30,38s As such, CSF protein 
elevation is neither sensitive nor specific for making the diagnosis of neurosyphilis.
Several novel biomarkers for neurosyphilis have been evaluated.42,43s CSF CXCL13, for 
example, was found to have a sensitivity of 90% and a specificity of 37% for symptomatic 
neurosyphilis at a low cutoff value, while at a high cutoff value, it had a specificity of 79% 
and a sensitivity of 41% in HIV infected patients.32 While this and other studies suggest that 
CXCL13 might provide some added value to existing CSF tests, particularly in HIV infected 
patients,44s none of the novel biomarkers to date have found a place in clinical practice. New 
and enhanced diagnostics for neurosyphilis are needed
Management
Currently, the CDC recommends that a CSF examination be performed in all persons with 
serological evidence of syphilis who have neurological signs and/or symptoms, and in 
asymptomatic persons with syphilis whose serological titers do not decline four-fold 
following stage-appropriate therapy.19
The Role of CSF Examination in Patients without Neurological Signs and/or Symptoms 
(with a Particular Focus on HIV-Infected Persons)
There has never been any controversy over the critical importance of CSF examinations in 
persons with neurologic signs and/or symptoms. However, while a significant proportion of 
asymptomatic patients with early syphilis have evidence of neuroinvasion and CSF 
abnormalities,20,45s there are no data to suggest that enhanced therapy beyond a single 
intramuscular 2.4 MU dose of benzathine penicillin G improves their long-term outcomes. 
In the pre-antibiotic era, the rationale was clear: experts advocated CSF examination in all 
patients regardless of symptoms because abnormal CSF examinations in persons with 
syphilis predicted poor long term neurological outcomes in asymptomatic patients.3 
Asymptomatic patients with a normal CSF examination were unlikely to develop long-term 
neurologic complications of syphilis unless their Wasserman titers increased.46s CSF 
abnormalities were less common in late syphilis, and asymptomatic patients with late 
syphilis and a normal CSF examination at 5 years were highly unlikely to develop tertiary 
complications.46s
Following the introduction of penicillin, the rates of neurosyphilis dramatically declined, 
and routine CSF examination in asymptomatic patients fell out of favor. The HIV epidemic 
re-ignited the debate over the need for CSF examination in asymptomatic patients, due to 
multiple reports of treatment failures in HIV-infected persons treated with CDC-
recommended penicillin regimens. 47–49s Patients with HIV and syphilis, particularly if their 
RPR titer is greater than or equal to 1:32, or they have a CD4 count less than or equal to 350 
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cells/mm3, may be found to have CSF abnormalities consistent with asymptomatic 
neurosyphilis4,50,51s Most concerning, a small study by Lukehart et al. found that 2 out of 4 
persons without neurologic symptoms who were found to have T. pallidum in their CSF 
failed to clear the organism after a single dose of 2.4 MU of BPG, and a third was deemed to 
have failed therapy based on persisting CSF abnormalities. All three patients who failed 
therapy were HIV positive.20 However, the significance of asymptomatic neurosyphilis in 
the penicillin era, even in patients with HIV, remains unclear. No studies have followed 
untreated HIV-infected persons with asymptomatic neurosyphilis to see whether this predicts 
progression to symptomatic neurosyphilis. Such a study would be logistically and ethically 
problematic. Observational studies, in general, have not showed an increase in neurosyphilis 
cases among HIV-infected persons with early syphilis treated with a single dose of 2.4 MU 
of BPG, but the follow-up data for most of these studies were limited.52,53s A recent study in 
which a CSF examination was done an average of 8 months after treatment in 64 patients 
with HIV at high risk of neurosyphilis (RPR >=1:32 and/or CD4<350) treated with a single 
2.4 MU dose of BPG found only one with asymptomatic neurosyphilis. No patients had 
developed symptomatic neurosyphilis.54s
In summary, there is insufficient evidence at present to suggest that identification of 
asymptomatic neurosyphilis in the antibiotic era helps to predict treatment failure even in 
patients with HIV. A randomized trial to determine whether a strategy of immediate lumbar 
puncture followed by therapy based on CSF results in better serological and functional 
outcomes in patients with syphilis who are at high risk for neuroinvasion is underway 
(ClinicalTrials.gov Identifier: NCT02031146).
The Role of CSF Examination in Persons whose Serological Titers Fail to Decline 
Appropriately following Stage-Directed Therapy
Patients who do not achieve a four-fold decline in nontreponemal serological titers within a 
specified period of time (12 months in early syphilis and 24 months in late syphilis) 
following appropriate stage-directed therapy are termed “serofast,” and the CDC 
recommends CSF examination in such persons. “Serofast” may also in some cases refer to 
patients who achieve a fourfold decline in non treponemal titer but do not completely revert 
from reactive to nonreactive.55s The CDC recommendation is based on pre-penicillin era 
data that suggest that up to 25% of persons with early syphilis who remain serofast (here the 
latter “serofast” definition applied) will progress to tertiary neurosyphilis.6 There was, 
however, no association between the serofast state and progression to tertiary neurosyphilis 
in those with late latent syphilis. In the penicillin era, one case series from China did report 
on 17 HIV negative patients with secondary syphilis whose RPR titers declined fourfold but 
failed to revert to negative 24 months after treatment, who subsequently developed 
neurosyphilis. However, only four of these 17 patients had neurologic symptoms.56s Several 
studies have assessed short-term serological outcomes following re-treatment of serofast 
persons (i.e. those whose titers fail to decline four-fold following stage-appropriate therapy),
57,58s
 but none have assessed long-term outcomes. Whether a CSF examination improves 
outcomes among asymptomatic persons who are serofast following stage-appropriate 
antibiotic therapy is not known.
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The Role of Antibiotic Regimens Other than Aqueous Crystalline Penicillin or Procaine 
Penicillin in the Treatment of Neurosyphilis
Several small observational studies suggest that intravenous ceftriaxone for 10 to 14 days is 
a reasonable alternative regimen. 59–61s Of interest, 3 weekly doses of 2.4 MU of BPG 
intramuscularly was a recommended treatment option for neurosyphilis through the 1982 
CDC STD Treatment Guidelines.62s However, reports surfaced that these doses did not 
achieve consistent treponemicidal levels in the CSF.63s Despite decades of use for 
neurosyphilis, and good clinical responses, 64s the recommendation to use 3 doses of 2.4 
MU of BPG to treat neurosyphilis was ultimately abandoned. Whether treponemicidal 
concentrations in the CSF are needed to control neurosyphilis in patients with a robust 
immune system is not clear.
Summary
In summary, reliable estimates of the prevalence of neurosyphilis in the modern era are 
lacking and because there are no gold standard tests, and much of the data comes from the 
pre-antibiotic era, diagnosis of neurosyphilis is challenging and a source of controversy. 
Definitions of neurosyphilis differ between surveillance and clinical guidelines, which may 
lead to added confusion over management. The need for a CSF examination in 
asymptomatic patients is debated, though at present, there is insufficient evidence to suggest 
that the identification of asymptomatic neurosyphilis in the antibiotic era helps to predict 
treatment failure, even in patients with HIV. The management of serofast patients is 
controversial, and complicated by differing definitions. Finally, the efficacy of antibiotics 
other than IV penicillin in the treatment neurosyphilis is not well established.
In a preface to their seminal text entitled “Neurosyphilis,” published in 1946, Merritt, 
Adams and Solomon write, “Among the consequences of the syphilitic infection, 
involvement of the central nervous system stands first in frequency and gravity. Considering 
this fact, it may seem odd that our knowledge of syphilis of the nervous system has been of 
such slow growth. Even today many fundamental problems remain unresolved…”5 More 
than 70 years later, critical knowledge gaps and important controversies remain in 
neurosyphilis epidemiology, diagnosis and treatment. As syphilis incidence continues to 
increase unabated in many countries around the world, it is critical, now more than ever, to 
address these.
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